Antiepileptic Drug Carbamazepine in Treatment of Bronchial Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00207428|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : May 16, 2006
|Condition or disease||Intervention/treatment||Phase|
|Bronchial Asthma||Drug: Carbamazepine||Phase 4|
Effective therapy of asthma still remains quite serious problem. According current opinion of leading specialists, asthma is an inflammatory disorder. But asthma also is a paroxysmal disorder: many specialists underline paroxysmal clinical picture of asthma. According to some authors, neurogenic inflammation may play important role in asthma mechanism. But migraine and trigeminal neuralgia are also neurogenic inflammatory paroxysmal diseases, and some antiepileptic drugs, like carbamazepine and valproates, are very effective in therapy of these diseases - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, we can suppose a possibility that some antiepileptic drugs also may show high efficacy in asthma therapy. Taken in consideration this hypothesis, we performed a double-blind, placebo-controlled 3-month trial for evaluation of carbamazepine efficacy in treatment of patients with mild-to-severe bronchial asthma.
Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||65 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Randomized, Placebo Controlled, Double Blind Study of Carbamazepine in Treatment of Bronchial Asthma|
|Study Start Date :||August 1999|
|Study Completion Date :||April 2000|
- At 3 months of treatment: Change from baseline of the PEFR (also %predicted); Number of patients without asthma symptoms
- At 3 months of treatment: PEFR before and after salbutamol inhalation;
- Difference in PEFR pm-am (in %); The daily (daytime and night-time) symptoms scores; Use of other antiasthmatic medication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00207428
|Principal Investigator:||Merab Lomia, MD, PhD||"Rea" Rehabilitation Centre|
|Study Director:||Manana Tchaia, MD||Centre of Chinese Medicine|